Published in Am J Med on December 01, 2008
The increasing burden of imported chronic hepatitis B--United States, 1974-2008. PLoS One (2011) 1.37
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am J Pathol (2011) 1.16
Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep (2011) 0.97
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Liver cirrhosis. Lancet (2008) 6.11
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol (2011) 2.20
Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology (2006) 2.11
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol (2007) 1.73
Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A (2009) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.62
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res (2008) 1.48
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems. Biophys J (2002) 1.35
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. Biomacromolecules (2007) 1.29
Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology (2003) 1.27
Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology (2007) 1.23
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20
Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem (2004) 1.13
Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol (2010) 1.12
Atomic force microscopy reveals aggregation of gastric mucin at low pH. Biomacromolecules (2005) 1.11
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09
EUS-guided liver biopsy: a procedure looking for an indication. Gastrointest Endosc (2009) 1.08
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (2013) 1.03
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01
Viscoelastic properties and dynamics of porcine gastric mucin. Biomacromolecules (2005) 1.01
Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol (2009) 0.99
Clinical utility of interleukin-28B testing in patients with genotype 1. Hepatology (2012) 0.98
Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.97
Health care quality measurement in the care of patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 0.96
Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep (2004) 0.95
Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol (2011) 0.95
Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol (2012) 0.94
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int (2010) 0.94
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology (2009) 0.93
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos (2011) 0.92
Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol (2007) 0.91
Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. J Lipid Res (2005) 0.91
Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther (2012) 0.89
Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones. Gastroenterology (2004) 0.87
Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am (2010) 0.86
Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res (2004) 0.86
Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol (2007) 0.85
Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr (2013) 0.84
Lack of the intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice. Am J Physiol Gastrointest Liver Physiol (2004) 0.84
Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology (2006) 0.83
Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol (2015) 0.83
Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology (2006) 0.82
Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. Scand J Gastroenterol (2008) 0.82
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int (2015) 0.82
Early TIPS to improve survival in acute variceal bleeding. N Engl J Med (2010) 0.80
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology (2012) 0.80
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. J Gastroenterol Hepatol (2011) 0.80
Antiviral therapy for treatment naïve patients with hepatitis C virus. Gastroenterol Clin North Am (2004) 0.79
Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis (2005) 0.78
Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation (2017) 0.77
Eltrombopag in patients with chronic liver disease. Expert Opin Pharmacother (2013) 0.77
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation (2017) 0.77
Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis. Antivir Ther (2010) 0.77
Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin North Am (2006) 0.76
The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol (2007) 0.76
The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites. Dig Dis Sci (2007) 0.75
Serum Ammonia in Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis. J Clin Gastroenterol (2016) 0.75
Erratum: Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration-Controlled Transient Elastography. Am J Gastroenterol (2016) 0.75